THE THERAPEUTIC EFFECT OF ALLOPURINOL IN FATTY LIVER DISEASE IN RATS

Background. Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD).Aim. We therefore aimed at evaluating the influence of allopurinol on the course of NAFLD in rats.Study Design. We divided 21 mature albino Sprague Dawley rats into three groups: controls (n = 7, normal diet for 12 weeks); NAFLD rat models (by feeding water containing 30% fructose for first 8 weeks) treated with allopurinol subsequently for the next 4 weeks (n = 7); and similar case treated with placebo (saline) subsequently for the next 4 weeks (n = 7).Methods. We compared the histopathological scores, IL-1 and IL-2 immunoexpression levels across the groups. Liver histopathological score was determined by observing the steatosis (the percentage of liver cells containing fat): <25% = 1+, 25% -50% = 2+, 51% -75% = 3+, >75% = 4+; inflammation and necrosis: 1 focus per low-power field = 1+; and 2 or more foci = 2+. The number of liver IL-1 and IL-2 positive cells was measured by systematically scoring at least 100 hepatocyte cells per field in 10 fields of tissue sections by a magnification of 100. Results. Xanthine oxidase (XO) activity and lipid peroxidation was significantly different in the allopurinol group compared to the saline group (XO; 0.098 +/- 0.006 mU/mg vs. 0.162 +/- 0.008 mU/mg, p = 0.01, 0.116 +/- 0.040 nmol malondialdehyde/mg versus 0.246 +/- 0.040 nmol malondialdehyde /mg, p = 0.01). The allopurinol group had lower histopathological scores, IL-1 and IL-2 immunoexpression levels in the liver compared to the saline group (2.13 +/- 0.35 against 5.45 +/- 0.24, p = 0.003, IL-1; 5.76 +/- 0.43 against 12.85 +/- 3.26, p = 0.023, IL-2; 8.55 +/- 1.14 against 56.23 +/- 7.12, p = 0.002).Conclusions. Allopurinol has a therapeutic role against the progression of NAFLD of the rats.